Abstract
This study aimed to explore effects of adjunctive treatment with N-acetyl cysteine (NAC) on markers of inflammation and neurogenesis in bipolar depression. This is a secondary analysis of a placebo-controlled randomised trial. Serum samples were collected at baseline, week 8, and week 32 of the open-label and maintenance phases of the clinical trial to determine changes in interleukin (IL)-6, IL-8, IL-10, tumour necrosis factor-α (TNF-α), C-reactive protein (CRP) and brain-derived neurotrophic factor (BDNF) following adjunctive NAC treatment, and to explore mediation and moderator effects of the listed markers. Levels of brain-derived neurotrophic factor (BDNF), tumour necrosis factor-α (TNF-α), C-reactive protein (CRP), interleukins (IL) -6, 8, or 10 were not significantly changed during the course of the trial or specifically in the open-label and maintenance phases. There were no mediation or moderation effects of the biological factors on the clinical parameters. The results suggest that these particular biological parameters may not be directly involved in the therapeutic mechanism of action of adjunctive NAC in bipolar depression.
References
Feb 1, 1991·Clinical Pharmacokinetics·M R Holdiness
Oct 9, 2002·Archives of General Psychiatry·Helena Chmura KraemerW Stewart Agras
Nov 8, 2003·Critical Care Medicine·Ross L PatersonNigel R Webster
Jun 17, 2008·Pediatric Research·Manjeet K PaintliaInderjit Singh
Dec 9, 2008·Behavioural Brain Research·Olivia DeanMaarten van den Buuse
Mar 2, 2010·Peritoneal Dialysis International : Journal of the International Society for Peritoneal Dialysis·Marcelo M NascimentoBjörn Anderstam
Aug 6, 2010·Journal of Psychiatric Research·Lindsay M Reynolds, Gavin P Reynolds
Oct 13, 2010·Molecular Psychiatry·J AlonsoR C Kessler
Dec 2, 2010·Journal of Psychiatry & Neuroscience : JPN·Olivia DeanMichael Berk
Jul 2, 2011·Journal of Affective Disorders·Michael BerkGin S Malhi
Dec 23, 2011·Revista brasileira de psiquiatria : orgão oficial da Associação Brasileira de Psiquiatria, Asociación Psiquiátrica de la América Latina·Pedro V MagalhãesMichael Berk
Aug 16, 2012·BMC Medicine·Michael BerkGin S Malhi
Jan 31, 2013·The American Journal of Psychiatry·Davy VancampfortMarc De Hert
Feb 2, 2013·Trends in Pharmacological Sciences·Michael BerkOlivia M Dean
Mar 16, 2013·The Australian and New Zealand Journal of Psychiatry·Pedro Vieira da Silva MagalhãesMichael Berk
Apr 27, 2013·Biochimica Et Biophysica Acta·Yuval SamuniMichael Berk
Apr 29, 2014·Journal of Affective Disorders·Menan A RabieRania El-Sawy Mahmoud
Jul 9, 2014·The Journal of Clinical Psychiatry·Michael BerkGin S Malhi
Apr 30, 2015·Clinical Biochemistry·Mohamed Montassar LasramNajoua Gharbi
Sep 22, 2015·Lancet·Iria GrandeEduard Vieta
Mar 19, 2016·Bipolar Disorders·Joshua D RosenblatRoger S McIntyre
May 4, 2016·The Journal of Clinical Psychiatry·Brisa S FernandesMichael Berk
Nov 3, 2016·Expert Opinion on Drug Metabolism & Toxicology·Alessandro MinariniGian Maria Galeazzi
Nov 2, 2016·Psychiatry and Clinical Neurosciences·Ekaterina SigitovaJiří Raboch
Aug 5, 2017·Medical Image Analysis·Eli GibsonDean C Barratt
Citations
Sep 6, 2019·Nutrients·Deanna M Minich, Benjamin I Brown
Jul 30, 2019·Frontiers in Psychiatry·Gara Arteaga-HenríquezHemmo A Drexhage
Jan 25, 2020·Acta Neuropathologica Communications·Amin MottahedinNathalie Strazielle
Feb 27, 2020·Antioxidants·Lourdes Alvarez-ArellanoJuan Carlos Corona
Feb 23, 2021·Expert Opinion on Pharmacotherapy·Ahmad Sleem, Rif S El-Mallakh
Mar 25, 2021·British Journal of Pharmacology·Irena SmagaMałgorzata Filip
Jul 30, 2020·European Journal of Pharmacology·Amir Hossein FaghfouriAlireza Ostadrahimi
Aug 27, 2021·Journal of Psychiatric Research·Chiara C BortolasciKen Walder